Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
复制标题
DOI：
10.1177/1352458512446036
复制
发表时间：
2012-12-01
影响因子：
5.8
通讯作者：
Fogdell-Hahn, Anna
中科院分区：
文献类型：
--
作者：
Jungedal, Roger;Lundkvist, Malin;Fogdell-Hahn, Anna
背景：针对干扰素β（IFN β）的中和抗体（NAb）导致多发性硬化患者的治疗效果丧失。在常规数据的横断面分析中，2003-2004年期间接受IFN β治疗的多发性硬化患者中NAb的血清阳性率为32%.Objectives：本研究的目的是调查2009- 2010年期间NAb的血清阳性率、NAb滴度水平和用于治疗多发性硬化患者的IFN α制剂是否发生了变化。方法：本研究对2009- 2010年1296例患者的NAb进行了检测。结果：2009 - 2010年NAb的血清阳性率下降至19%，与2003-2004年相比有显著性差异（P < 0.05）。
Background: Neutralizing antibodies (NAbs) against interferon beta (IFN beta) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFN beta during 2003-2004 was 32% in a cross-sectional analysis of routine data.Objectives: The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNa preparations used for treatment of multiple sclerosis patients had changed in 2009-2010.Methods: This study included 1296 patients, analysed for NAbs with the myxovirus resistance protein A gene expression assay in 2009-2010.Results: The seroprevalence of NAbs had decreased to 19% in 2009-2010, which is significantly lower compared with the previous study in 2003-2004 (p